Edwards Lifesciences enters new $750M five-year revolving credit facility, replaces 2018 agreement

Edwards Lifesciences Corp

New $750M unsecured multi-currency revolving credit facility matures July 15, 2027.
Pricing improved vs. 2018 facility; margin tied to leverage ratio or debt ratings.
Facility includes options for increase up to $250M additional and multicurrency sub-limits.
No amounts drawn as of July 15, 2022; proceeds for general corporate purposes and refinancing.
Terminated the existing 2018 credit agreement on same date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.